首例t(8;20)易位的M_2-ANLL白血病重组位点的初步研究

The initial research on the site of recombination of a new M_2-ANLL case with t(8,20) translocation

对临床上确诊为M2－ANLL（acutenon－lymphocyteleukemia）的病例，首先进行骨髓细胞染色体的核型分析，经G显带和R显带确定为t（8；20）（q22；P23）易位，是一种新的变异型．为进行分子生物学研究，分别设计引物，反转录扩增检测ETO基因CDNA3’-端顺序和AML；－ETOM合转录物．实验证明了该易位为8号染色体上的ETO基因受累，但AML1－ETO融合转录物检测为阴性，从分子水平上排除了经典的t（：21）易位的可能性．说明了该病例为t（8；20）易位。ETO基因受累的新变异型白血病。

This paper first reported the initial molecular biological research focused on a newM2-ANLL case with t (8, 20) chromosome translocation. The result excluded the possibilityof t(8,21) translocation and identified that the ETO gene on chromosome 8 was responsiblefor this case.